Director of Haematology
St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
Melbourne, Victoria, Australia
• Dr Quach is Professor of Haematology at the University of Melbourne (UoM), chair of the Myeloma Working Party of the ALLG (Australasian Leukaemia and Lymphoma Group) and deputy chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia. She obtained her medical degree at UoM and earned her doctorate degree from UoM in 2010, on novel therapeutics and immunology in myeloma
• Her clinical area of expertise is in multiple myeloma. She is strongly involved in clinical and translational research, focusing on novel treatments for the management of hematological cancers and ensuring access to effective therapies across Australia. Her translational research focuses on myeloma immunology and the cancer microenvironment. She has been actively engaged in the DREAMM clinical trial development program, serving as a coauthor in both the DREAMM-2 publication in Lancet Oncology (2020) and in the DREAMM-5 study design publication in Future Oncology (2021). Additionally, Dr Quach is the principal investigator of a number of myeloma trials, including the AMaRC 19-02/BelaCarD study evaluating belantamab mafodotin plus carfilzomib/dexamethasone in patients with 2L+ RRMM
• Dr Quach has secured a significant amount of research funding toward myeloma research through competitive grants, industry collaborations, and philanthropy, and is highly published in the field of multiple myeloma. She has also published specifically on the management of elderly patients with multiple myeloma, including primary articles, review articles, and guidance documents. In 2023, Dr Quach was the senior author on, “The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia”
BCMA-targeted treatment options for elderly patients in early RRMM
Friday, September 29, 2023
12:15 PM – 12:25 PM EEST